This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Cerebral microvascular ischemic disease is a leading cause of dementia in the adult population. In their meta-analysis of data from more than 70,000 patients with ischemic stroke, Dr. Georgakis and colleagues examined the association between severity of white matter disease on baseline CT or MRI with 4 outcome measures—all-cause dementia, long-term functional impairment, recurrent stroke, or death due to any cause. Using an elegant mixed-effects regression model, adjusting for multiple hypothesis testing, the investigators observed a significant increased risk of each of these outcome measures among patients with moderate to severe white matter disease when compared with patients with mild to no white matter disease. In response, Dr. Gupta reminds the reader that white matter disease is etiologically heterogeneous and does not always indicate microvascular ischemia—it may be migraine or medication-related—and therefore may not universally portend an increased risk of vascular dementia or other morbidity. The investigators acknowledge this limitation of their meta-analysis; however, the relationship between (nonspecific) white matter disease and clinical outcomes remains robust. Whether the effect may be more strongly driven by patients with microvascular white matter disease and is attenuated by patients with toxic or nonvascular white matter disease remains to be clarified.
Cerebral microvascular ischemic disease is a leading cause of dementia in the adult population. In their meta-analysis of data from more than 70,000 patients with ischemic stroke, Dr. Georgakis and colleagues examined the association between severity of white matter disease on baseline CT or MRI with 4 outcome measures—all-cause dementia, long-term functional impairment, recurrent stroke, or death due to any cause.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2020 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
